+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07692204

Phase 2 Study of SAR445877 as Monotherapy for Adults With Advanced Gastric or Gastroesophageal Junction Cancer in China

Led by Sanofi · Updated on 2026-07-20

30

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the preliminary effectiveness and safety of SAR445877 as a single treatment for Chinese adults aged 18 years and older with advanced gastric cancer or gastroesophageal junction cancer. This Phase 2, open-label study focuses on participants with advanced unresectable or metastatic disease who have relapsed after at least one prior treatment regimen, which may or may not have included anti-PD1PD-L1-based therapies. Participants with HER2-positive tumors must have progressed after HER2-targeted therapy, and those with MSI-H or mismatch repair-deficient tumors are excluded. The study involves two groups randomized to receive different doses of SAR445877 administered through intravenous infusion. The treatment cycles last 14 days each, with dosing and serum concentrations monitored closely during the first and third cycles. The study will assess various pharmacokinetic parameters, immune response markers, and safety outcomes, including treatment-emergent adverse events. Participants will be observed for up to approximately two years to evaluate objective response rate and other clinical benefit measures. During the study, participants will undergo regular assessments including imaging to measure tumor response per RECIST 1.1 criteria. Blood samples will be collected to evaluate drug levels and immune activity. Safety will be monitored throughout treatment and for 30 days following the last dose. The study aims to measure time to response, duration of response, progression-free survival, and overall survival, providing important data on SAR445877s potential role in treating advanced gastric or gastroesophageal junction cancer.

CONDITIONS

Brief Title

A Dose Optimization/Expansion Study of SAR445877 in Adult Chinese Participants With Advanced Gastric or Gastroesophageal Junction Cancer

Research Team

T

Trial Transparency email recommended (Toll free for US & Canada)

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here